Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,716.09
(
0.25%
)
US TECH 100
24,299.60
(
0.69%
)
Dow Jones
46,993.26
(
0.10%
)
Brent Oil
100.60
(
-0.05%
)
Bitcoin
74,200.55
(
0.35%
)
News Focus
News Focus
Post# of 257253
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 842
Posts 122793
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: bladerunner1717 post# 94518

Tuesday, 04/20/2010 11:04:20 PM

Tuesday, April 20, 2010 11:04:20 PM

Post# of 257253

I have friends who are now on Atripla. Is there any compelling reason for them to switch to TMC278 + Truvada, should that regimen be approved?

TMC278 presumably has a lower rate of SAE’s than Sustiva, the corresponding non-nuke component of Atripla. I use the word presumably because JNJ has not yet disclosed the data from the TMC278 phase-3 trials.


“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now